Astrana Health, Inc. (NASDAQ:ASTH) Shares Acquired by Quantbot Technologies LP

Quantbot Technologies LP increased its stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) by 152.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,651 shares of the company’s stock after acquiring an additional 6,433 shares during the quarter. Quantbot Technologies LP’s holdings in Astrana Health were worth $336,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp acquired a new stake in shares of Astrana Health during the third quarter worth about $91,966,000. Geode Capital Management LLC purchased a new position in Astrana Health during the 3rd quarter worth approximately $58,995,000. FMR LLC acquired a new position in Astrana Health during the third quarter worth approximately $48,413,000. Charles Schwab Investment Management Inc. lifted its stake in Astrana Health by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 471,329 shares of the company’s stock valued at $14,861,000 after buying an additional 23,533 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of Astrana Health by 122.3% in the fourth quarter. Royce & Associates LP now owns 255,552 shares of the company’s stock valued at $8,058,000 after acquiring an additional 140,584 shares during the period. 52.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Stifel Nicolaus reduced their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Robert W. Baird cut their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Truist Financial lowered their target price on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Bank of America cut their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Macquarie upgraded Astrana Health to a “hold” rating in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Price Performance

ASTH stock opened at $30.54 on Friday. The firm has a 50 day moving average of $33.85 and a 200-day moving average of $41.99. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 1.37 and a beta of 1.30. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a 12-month low of $23.12 and a 12-month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. As a group, equities analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.